Morgan Stanley raised the firm’s price target on Organogenesis (ORGO) to $6 from $4 and keeps an Equal Weight rating on the shares, citing a “robust” Q4 report with visibility into a stronger financial performance in 2025. Though longer term drivers are tracking inline with expectations, the firm stays Equal Weight, citing local coverage determination overhangs and an implied back-end weighted ramp for 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis Holdings Reports Strong Q4 Earnings Amid Challenges
- Dell reports mixed Q4 results, Intel delays Ohio chip factory: Morning Buzz
- Organogenesis price target raised to $7 from $6 at BTIG
- Organogenesis Holdings Reports Strong Q4 2024 Results
- Organogenesis sees FY25 revenue $480M-$535M, consensus $472.94M